Today’s the day for Bristol-Myers-Celgene

After three months of debate, dissent, and seemingly infinite PowerPoint slides, the end of the Bristol-Myers-Celgene saga is upon us.

This morning, at 10 a.m. ET, Bristol shareholders will vote on whether to approve the company’s $74 billion merger with Celgene. Fans of shareholder meetings can livestream the proceedings here. But be warned: A pair of endorsements from influential advisory firms put an end to most of the swashbuckling, and the deal is expected to pass with ease.

But that doesn’t mean the story is over. Stay tuned to STAT after the final vote for some analysis of what’s next for the combined company.